Michael Song

3.3k total citations · 1 hit paper
49 papers, 2.5k citations indexed

About

Michael Song is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Michael Song has authored 49 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Immunology, 22 papers in Dermatology and 11 papers in Rheumatology. Recurrent topics in Michael Song's work include Psoriasis: Treatment and Pathogenesis (39 papers), Dermatology and Skin Diseases (20 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Michael Song is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (39 papers), Dermatology and Skin Diseases (20 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Michael Song collaborates with scholars based in United States, Canada and United Kingdom. Michael Song's co-authors include B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Peter Foley, Kenneth B. Gordon, Kristian Reich, April W. Armstrong, L. Puig and Tsen‐Fang Tsai and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Michael Song

48 papers receiving 2.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

2017 537 citations Kristian Reich, April W. Armstrong et al. Journal of the American Academy of Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael Song	2.1k	1.3k	682	450	425	49	2.5k
Yaung‐Kaung Shen	2.6k 1.2×	1.4k 1.1×	971 1.4×	460 1.0×	673 1.6×	37	3.0k
Norman Wasel	1.6k 0.8×	949 0.7×	388 0.6×	303 0.7×	237 0.6×	20	2.0k
Ming-Chun Hsu	1.5k 0.7×	824 0.6×	323 0.5×	270 0.6×	232 0.5×	14	1.7k
Emily Edson‐Heredia	1.4k 0.6×	992 0.8×	356 0.5×	282 0.6×	177 0.4×	40	1.9k
Darryl Toth	1.2k 0.6×	954 0.7×	321 0.5×	228 0.5×	160 0.4×	33	1.7k
Zenas Z N Yiu	1.2k 0.6×	898 0.7×	308 0.5×	286 0.6×	127 0.3×	72	1.8k
Isabelle Hampele	1.3k 0.6×	751 0.6×	344 0.5×	256 0.6×	217 0.5×	8	1.6k
Gregory Kricorian	1.4k 0.7×	718 0.6×	387 0.6×	278 0.6×	290 0.7×	23	1.7k
Marianne Notter	1.3k 0.6×	732 0.6×	342 0.5×	266 0.6×	212 0.5×	9	1.6k
Thomas Salko	1.3k 0.6×	720 0.6×	333 0.5×	253 0.6×	212 0.5×	5	1.6k

Countries citing papers authored by Michael Song

Since Specialization

Citations

This map shows the geographic impact of Michael Song's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Song with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Song more than expected).

Fields of papers citing papers by Michael Song

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Song. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Song. The network helps show where Michael Song may publish in the future.

Co-authorship network of co-authors of Michael Song

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Song. A scholar is included among the top collaborators of Michael Song based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Song. Michael Song is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lerner, Debra, Michael Song, Lisa Belter, et al.. (2025). Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1. Journal of Pain and Symptom Management. 71(1). 89–98.e3.

Alavi, Afsáneh, Susan D. Mathias, Hilary H. Colwell, et al.. (2021). Development of a patient-reported outcome questionnaire to assess signs and symptoms of hidradenitis suppurativa: The Hidradenitis Suppurativa Symptom Diary. Journal of the American Academy of Dermatology. 88(5). 1123–1125. 1 indexed citations

Griffiths, C.E.M., Kim Papp, Michael Song, et al.. (2020). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. Journal of Dermatological Treatment. 33(2). 848–856. 32 indexed citations

Reich, Kristian, April W. Armstrong, Peter Foley, et al.. (2020). Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American Journal of Clinical Dermatology. 21(6). 881–890. 27 indexed citations

Gordon, Kenneth B., April W. Armstrong, Peter Foley, et al.. (2019). Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. Journal of Investigative Dermatology. 139(12). 2437–2446.e1. 76 indexed citations

McInnes, Iain B., L. Puig, Alice B. Gottlieb, et al.. (2019). Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. The Journal of Rheumatology. 46(11). 1458–1461. 9 indexed citations

Reich, Kristian, C.E.M. Griffiths, Kenneth B. Gordon, et al.. (2019). Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology. 82(4). 936–945. 63 indexed citations

Armstrong, April W., Peter Foley, Yasmine Wasfi, et al.. (2018). LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2. 98. 3 indexed citations

Armstrong, April W., Kristian Reich, Peter Foley, et al.. (2018). Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. American Journal of Clinical Dermatology. 20(1). 155–164. 34 indexed citations

10.

Gordon, Kenneth B., April W. Armstrong, Chenglong Han, et al.. (2018). Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. Journal of the European Academy of Dermatology and Venereology. 32(11). 1940–1949. 60 indexed citations

11.

Wu, Yang‐Chang, Qingmin Wang, Michael Song, et al.. (2017). Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis. BMC Complementary and Alternative Medicine. 17(1). 439–439. 40 indexed citations

12.

Reich, Kristian, April W. Armstrong, Peter Foley, et al.. (2017). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology. 76(3). 418–431. 537 indexed citations breakdown →

13.

Armstrong, April W., L. Puig, Richard G. Langley, et al.. (2017). Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. Journal of Dermatological Treatment. 30(1). 27–34. 25 indexed citations

14.

Langley, Richard G., Tsen‐Fang Tsai, Susan Flavin, et al.. (2017). Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial. British Journal of Dermatology. 178(1). 114–123. 245 indexed citations

15.

Kavanaugh, Arthur, L. Puig, Alice B. Gottlieb, et al.. (2016). Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Annals of the Rheumatic Diseases. 75(11). 1984–1988. 126 indexed citations

16.

Kavanaugh, Arthur, L. Puig, Alice B. Gottlieb, et al.. (2015). SAT0563 Long Term Improvements in Physical Function are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients. Annals of the Rheumatic Diseases. 74. 864–864. 2 indexed citations

17.

Kavanaugh, Arthur, Christopher T. Ritchlin, Proton Rahman, et al.. (2014). Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Annals of the Rheumatic Diseases. 73(6). 1000–1006. 220 indexed citations

18.

Mun, Je‐Ho, Seung Chik Jwa, Michael Song, et al.. (2013). Proactive Treatment of Adult Facial Seborrhoeic Dermatitis with 0.1% Tacrolimus Ointment: Randomized, Double-blind, Vehicle-controlled, Multi-centre Trial. Acta Dermato Venereologica. 93(5). 557–561. 14 indexed citations

19.

Igarashi, Atsuyuki, et al.. (2011). Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial. The Journal of Dermatology. 39(3). 242–252. 176 indexed citations

20.

Tsai, Tsen‐Fang, Ji‐Chen Ho, Michael Song, et al.. (2011). Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). Journal of Dermatological Science. 63(3). 154–163. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact